121 related articles for article (PubMed ID: 32203205)
41. Characterization of spliceogenic variants located in regions linked to high levels of alternative splicing: BRCA2 c.7976+5G > T as a case study.
Montalban G; Fraile-Bethencourt E; López-Perolio I; Pérez-Segura P; Infante M; Durán M; Alonso-Cerezo MC; López-Fernández A; Diez O; de la Hoya M; Velasco EA; Gutiérrez-Enríquez S
Hum Mutat; 2018 Sep; 39(9):1155-1160. PubMed ID: 29969168
[TBL] [Abstract][Full Text] [Related]
42. Haplotype and quantitative transcript analyses of Portuguese breast/ovarian cancer families with the BRCA1 R71G founder mutation of Galician origin.
Santos C; Peixoto A; Rocha P; Vega A; Soares MJ; Cerveira N; Bizarro S; Pinheiro M; Pereira D; Rodrigues H; Castro F; Henrique R; Teixeira MR
Fam Cancer; 2009; 8(3):203-8. PubMed ID: 19123044
[TBL] [Abstract][Full Text] [Related]
43. Characterisation of unclassified variants in the BRCA1/2 genes with a putative effect on splicing.
Brandão RD; van Roozendaal K; Tserpelis D; Gómez García E; Blok MJ
Breast Cancer Res Treat; 2011 Oct; 129(3):971-82. PubMed ID: 21638052
[TBL] [Abstract][Full Text] [Related]
44. Germline variants in DNA repair genes associated with hereditary breast and ovarian cancer syndrome: analysis of a 21 gene panel in the Brazilian population.
da Costa E Silva Carvalho S; Cury NM; Brotto DB; de Araujo LF; Rosa RCA; Texeira LA; Plaça JR; Marques AA; Peronni KC; Ruy PC; Molfetta GA; Moriguti JC; Carraro DM; Palmero EI; Ashton-Prolla P; de Faria Ferraz VE; Silva WA
BMC Med Genomics; 2020 Feb; 13(1):21. PubMed ID: 32039725
[TBL] [Abstract][Full Text] [Related]
45. Reinterpretation of BRCA1 and BRCA2 variants of uncertain significance in patients with hereditary breast/ovarian cancer using the ACMG/AMP 2015 guidelines.
So MK; Jeong TD; Lim W; Moon BI; Paik NS; Kim SC; Huh J
Breast Cancer; 2019 Jul; 26(4):510-519. PubMed ID: 30725392
[TBL] [Abstract][Full Text] [Related]
46. Germline EMSY sequence alterations in hereditary breast cancer and ovarian cancer families.
Määttä KM; Nurminen R; Kankuri-Tammilehto M; Kallioniemi A; Laasanen SL; Schleutker J
BMC Cancer; 2017 Jul; 17(1):496. PubMed ID: 28738860
[TBL] [Abstract][Full Text] [Related]
47. Hereditary breast and ovarian cancer in Andalusian families: a genetic population study.
Pajares B; Porta J; Porta JM; Sousa CF; Moreno I; Porta D; Durán G; Vega T; Ortiz I; Muriel C; Alba E; Márquez A
BMC Cancer; 2018 Jun; 18(1):647. PubMed ID: 29884136
[TBL] [Abstract][Full Text] [Related]
48. Prediction of single-nucleotide substitutions that result in exon skipping: identification of a splicing silencer in BRCA1 exon 6.
Raponi M; Kralovicova J; Copson E; Divina P; Eccles D; Johnson P; Baralle D; Vorechovsky I
Hum Mutat; 2011 Apr; 32(4):436-44. PubMed ID: 21309043
[TBL] [Abstract][Full Text] [Related]
49. Implementation of next-generation sequencing for molecular diagnosis of hereditary breast and ovarian cancer highlights its genetic heterogeneity.
Pinto P; Paulo P; Santos C; Rocha P; Pinto C; Veiga I; Pinheiro M; Peixoto A; Teixeira MR
Breast Cancer Res Treat; 2016 Sep; 159(2):245-56. PubMed ID: 27553368
[TBL] [Abstract][Full Text] [Related]
50. Prevalence of BRCA1 and BRCA2 pathogenic and likely pathogenic variants in non-selected ovarian carcinoma patients in Brazil.
Cotrim DP; Ribeiro ARG; Paixão D; de Queiroz Soares DC; Jbili R; Pandolfi NC; Cezana C; de Cássia Mauro C; Mantoan H; Bovolim G; de Brot L; Torrezan GT; Carraro DM; Baiocchi G; da Cruz Formiga MN; da Costa AABA
BMC Cancer; 2019 Jan; 19(1):4. PubMed ID: 30606148
[TBL] [Abstract][Full Text] [Related]
51. Frequency of the ATM IVS10-6T-->G variant in Australian multiple-case breast cancer families.
Lindeman GJ; Hiew M; Visvader JE; Leary J; Field M; Gaff CL; Gardner RJ; Trainor K; Cheetham G; Suthers G; Kirk J
Breast Cancer Res; 2004; 6(4):R401-7. PubMed ID: 15217508
[TBL] [Abstract][Full Text] [Related]
52. Somatic mRNA Analysis of BRCA1 Splice Variants Provides a Direct Theranostic Impact on PARP Inhibitors.
Chevalier LM; Billaud A; Fronteau S; Dauvé J; Patsouris A; Verriele V; Morel A
Mol Diagn Ther; 2020 Apr; 24(2):233-243. PubMed ID: 32124385
[TBL] [Abstract][Full Text] [Related]
53. Male with an apparently normal phenotype carrying a BRCA1 exon 20 duplication in trans to a BRCA1 frameshift variant.
Block I; Mateu-Regué À; Do TTN; Miceikaite I; Sdogati D; Larsen MJ; Hao Q; Nielsen HR; Boonen SE; Skytte AB; Jensen UB; Høffding LK; De Nicolo A; Viel A; Tudini E; Parsons MT; Hansen TVO; Rossing M; Kruse TA; Spurdle AB; Thomassen M
Breast Cancer Res; 2024 Jan; 26(1):6. PubMed ID: 38195559
[TBL] [Abstract][Full Text] [Related]
54. Prognosis of BRCA1/2-negative breast cancer patients with HBOC risk factors compared with sporadic breast cancer patients without HBOC risk factors.
Ryu JM; Nam SJ; Kim SW; Lee JE; Chae BJ; Lee SK; Yu J
Jpn J Clin Oncol; 2020 Feb; 50(2):104-113. PubMed ID: 31926487
[TBL] [Abstract][Full Text] [Related]
55. An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers.
Przybytkowski E; Davis T; Hosny A; Eismann J; Matulonis UA; Wulf GM; Nabavi S
BMC Cancer; 2020 Mar; 20(1):197. PubMed ID: 32164626
[TBL] [Abstract][Full Text] [Related]
56. Cancer risk management among female BRCA1/2, PALB2, CHEK2, and ATM carriers.
Cragun D; Weidner A; Tezak A; Clouse K; Pal T
Breast Cancer Res Treat; 2020 Jul; 182(2):421-428. PubMed ID: 32445176
[TBL] [Abstract][Full Text] [Related]
57. [Characteristics of selected clinical features in BRCA1 mutation carriers affected with breast cancer undergoing preventive female genital tract surgeries].
Menkiszak J; Chudecka-Głaz A; Gronwald J; Bedner R; Cymbaluk-Płoska A; Wezowska M; Zielińska D; Rzepka-Górska I
Ginekol Pol; 2013 Sep; 84(9):758-64. PubMed ID: 24191513
[TBL] [Abstract][Full Text] [Related]
58. Potentially pathogenic germline CHEK2 c.319+2T>A among multiple early-onset cancer families.
Dominguez-Valentin M; Nakken S; Tubeuf H; Vodak D; Ekstrøm PO; Nissen AM; Morak M; Holinski-Feder E; Martins A; Møller P; Hovig E
Fam Cancer; 2018 Jan; 17(1):141-153. PubMed ID: 28608266
[TBL] [Abstract][Full Text] [Related]
59. Is there a genetic anticipation in breast and/or ovarian cancer families with the germline c.3481_3491del11 mutation?
El Tannouri R; Albuisson E; Jonveaux P; Luporsi E
Fam Cancer; 2018 Jan; 17(1):5-14. PubMed ID: 28493033
[TBL] [Abstract][Full Text] [Related]
60. Prophylactic oophorectomy reduces breast cancer penetrance during prospective, long-term follow-up of BRCA1 mutation carriers.
Kramer JL; Velazquez IA; Chen BE; Rosenberg PS; Struewing JP; Greene MH
J Clin Oncol; 2005 Dec; 23(34):8629-35. PubMed ID: 16314625
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]